China SXT Pharmaceuticals Inc Total Liabilities
China SXT Pharmaceuticals Inc total liabilities. Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) has total liabilities worth $5.05 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check China SXT Pharmaceuticals Inc (SXTC) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of China SXT Pharmaceuticals Inc (2016–2026)
Total liabilities of China SXT Pharmaceuticals Inc from 2016 to 2026. This chart illustrates how China SXT Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore China SXT Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
China SXT Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of China SXT Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA29.64 Million |
|
SECITS Holding AB (publ)
ST:SECI
|
Sweden | Skr83.32 Million |
|
Steakholder Foods Ltd
NASDAQ:STKH
|
USA | $877.00K |
|
Upsellon Brands Holdings Ltd
TA:CHR
|
Israel | ILA2.01 Million |
|
Time Out Group plc
LSE:TMO
|
UK | GBX120.06 Million |
|
Bessor Minerals Inc
V:BST
|
Canada | CA$123.70K |
|
iQ International AG
F:IQL
|
Germany | €47.82 Million |
Liability Composition Analysis (2016–2026)
This chart breaks down China SXT Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is China SXT Pharmaceuticals Inc's balance sheet.
Liquidity & Leverage Metrics
China SXT Pharmaceuticals Inc Total Liabilities Ratios Explained
China SXT Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China SXT Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China SXT Pharmaceuticals Inc (2016–2026)
The table below shows the annual total liabilities of China SXT Pharmaceuticals Inc from 2016 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $5.05 Million | -18.90% |
| 2025-03-31 | $6.22 Million | -32.33% |
| 2024-03-31 | $9.20 Million | -38.12% |
| 2023-03-31 | $14.86 Million | -13.19% |
| 2022-03-31 | $17.12 Million | -7.88% |
| 2021-03-31 | $18.59 Million | +51.10% |
| 2020-03-31 | $12.30 Million | +93.32% |
| 2019-03-31 | $6.36 Million | +45.54% |
| 2018-03-31 | $4.37 Million | +22.17% |
| 2017-03-31 | $3.58 Million | -35.57% |
| 2016-03-31 | $5.55 Million | -- |
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo,… Read more